Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 31.6% in the 4th quarter, Holdings Channel reports. The fund owned 21,039 shares of the company’s stock after selling 9,705 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Denali Therapeutics were worth $429,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in Denali Therapeutics during the 4th quarter valued at about $532,000. Proficio Capital Partners LLC bought a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $514,000. JPMorgan Chase & Co. boosted its position in shares of Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after buying an additional 14,324 shares during the period. Principal Financial Group Inc. grew its holdings in Denali Therapeutics by 13.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after buying an additional 149,939 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after acquiring an additional 843,996 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DNLI shares. Wedbush decreased their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. HC Wainwright decreased their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. B. Riley reissued a “buy” rating and set a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 price target for the company. Finally, Oppenheimer dropped their price objective on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $33.79.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $14.26 on Wednesday. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The business’s 50 day simple moving average is $14.20 and its 200 day simple moving average is $19.87. The firm has a market cap of $2.07 billion, a PE ratio of -5.17 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the company earned ($0.68) EPS. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.